Top

Published in:

Open Access 01-12-2010 | Review

Diagnosis and biomarkers of predementia in Alzheimer's disease

Authors: Orestes V Forlenza, Breno S Diniz, Wagner F Gattaz

Published in: BMC Medicine | Issue 1/2010

Abstract

In view of the growing prevalence of Alzheimer's disease (AD) worldwide, there is an urgent need for the development of better diagnostic tools and more effective therapeutic interventions. At the earliest stages of AD, no significant cognitive or functional impairment is detected by conventional clinical methods. However, new technologies based on structural and functional neuroimaging, and on the biochemical analysis of cerebrospinal fluid (CSF) may reveal correlates of intracerebral pathology in individuals with mild, predementia symptoms. These putative correlates are commonly referred to as AD-related biomarkers. The relevance of the early diagnosis of AD relies on the hypothesis that pharmacological interventions with disease-modifying compounds are likely to produce clinically relevant benefits if started early enough in the continuum towards dementia. Here we review the clinical characteristics of the prodromal and transitional states from normal cognitive ageing to dementia in AD. We further address recent developments in biomarker research to support the early diagnosis and prediction of dementia, and point out the challenges and perspectives for the translation of research data into clinical practice.

Available only for authorised users

Brookmeyer R, Gray S, Kawas C: Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998, 88: 1337-1342. 10.2105/AJPH.88.9.1337.PubMedCentral

Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM: Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007, 3: 186-191. 10.1016/j.jalz.2007.04.381.

Ziegler-Graham K, Brookmeyer R, Johnson E, Arrighi HM: Worldwide variation in the doubling time of Alzheimer's disease incidence rates. Alzheimers Dement. 2008, 4: 316-323. 10.1016/j.jalz.2008.05.2479.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984, 34: 939-944.

McKhann G, Hyman B, Jack C, Kawas C, Klunk W, Knopman D, Koroshetz W, Manly J, Mayeux R, Mohs R, Morris J, Weintraub S, Alzheimer's Disease Dementia Workgroup: Criteria for AD dementia. [http://www.alz.org/research/diagnostic_criteria/dementia_recommendations.pdf]

Albert M, DeKosky S, Dickson D, Dubois B, Feldman H, Fox N, Gamst A, Holtzman D, Jagust W, Petersen R, Snyder P, Mild Cognitive Impairment due to Alzheimer's Disease Workgroup: Criteria for mild cognitive impairment due to Alzheimer's disease. [http://www.alz.org/research/diagnostic_criteria/mci_reccomendations.pdf]

Nelson PT, Braak H, Markesbery WR: Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol. 2009, 68: 1-14. 10.1097/NEN.0b013e3181919a48.PubMedCentral

Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ: Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9: 119-128. 10.1016/S1474-4422(09)70299-6.PubMedCentral

Blass JP: Alzheimer's disease and Alzheimer's dementia: distinct but overlapping entities. Neurobiol Aging. 2002, 23: 1077-1084. 10.1016/S0197-4580(02)00036-2.

10.

Thal DR, Rüb U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K, Braak E, Braak H: Sequence of Aβ-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol. 2000, 59: 733-748.

11.

Thal DR, Rüb U, Orantes M, Braak H: Phases of A β-deposition in the human brain and its relevance for the development of AD. Neurology. 2002, 58: 1791-1800.

12.

Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, Smith GE, Dickson DW, Johnson KA, Petersen LE, McDonald WC, Braak H, Petersen RC: Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003, 62: 1087-1095.

13.

Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA: Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009, 66: 1469-1475. 10.1001/archneurol.2009.269.PubMedCentral

14.

Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999, 56: 303-308. 10.1001/archneur.56.3.303.

15.

Forlenza OV, Chiu E: Mild cognitive impairment: a concept ready to move on?. Cur Opin Psychiatry. 2008, 21: 529-532. 10.1097/YCO.0b013e328316c2ab.

16.

Petersen RC, Parisi JE, Dickson DW, Johnson KA, Knopman DS, Boeve BF, Jicha GA, Ivnik RJ, Smith GE, Tangalos EG, Braak H, Kokmen E: Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol. 2006, 63: 665-672. 10.1001/archneur.63.5.665.

17.

Small BJ, Fratiglioni L, Viitanen M, Winblad B, Bäckman L: The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population-based sample. Arch Neurol. 2000, 57: 839-844. 10.1001/archneur.57.6.839.

18.

Blacker D, Lee H, Muzikansky A, Martin EC, Tanzi R, McArdle JJ, Moss M, Albert M: Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch Neurol. 2007, 64: 862-871. 10.1001/archneur.64.6.862.

19.

Parra MA, Abrahams S, Fabi K, Logie R, Luzzi S, Della Sala S: Short term memory binding deficits in Alzheimer's disease. Brain. 2009, 132: 1057-1066. 10.1093/brain/awp036.

20.

Forlenza OV, Diniz BS, Nunes PV, Memoria CM, Yassuda MS, Gattaz WF: Diagnostic transitions in mild cognitive impairment subtypes. Int Psychogeriatr. 2009, 21: 1088-1095. 10.1017/S1041610209990792.

21.

Pereira FS, Yassuda MS, Oliveira AM, Forlenza OV: Executive dysfunction correlates with impaired functional status in older adults with varying degrees of cognitive impairment. Int Psychogeriatr. 2008, 20: 1104-1115. 10.1017/S1041610208007631.

22.

Stephan BC, Matthews FE, McKeith IG, Bond J, Brayne C, Medical Research Council Cognitive Function and Aging Study: Early cognitive change in the general population: how do different definitions work?. J Am Geriatr Soc. 2007, 55: 1534-1540. 10.1111/j.1532-5415.2007.01386.x.

23.

Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST: Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001, 56: 1133-1142.

24.

Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Bäckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC: Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004, 256: 240-246. 10.1111/j.1365-2796.2004.01380.x.

25.

Bruscoli M, Lovestone S: Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr. 2004, 16: 129-140. 10.1017/S1041610204000092.

26.

Mitchell A, Shiri-Feshki M: Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009, 119: 252-265. 10.1111/j.1600-0447.2008.01326.x.

27.

Visser P, Scheltens P, Verhey FR: Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?. J Neurol Neurosurg Psychiatry. 2005, 76: 1348-1354. 10.1136/jnnp.2004.047720.PubMedCentral

28.

Petersen RC: Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004, 256: 183-194. 10.1111/j.1365-2796.2004.01388.x.

29.

Busse A, Hansel A, Gühne U, Angermeyer MC, Riedel-Heller SG: Mild cognitive impairment: long-term course of four clinical subtypes. Neurology. 2006, 67: 2176-2185. 10.1212/01.wnl.0000249117.23318.e1.

30.

Fischer P, Jungwirth S, Zehetmayer S, Weiss-gram S, Hoenigschnabl S, Gelpi E, Krampla W, Tragl KH: Conversion of subtypes of mild cognitive impairment to Alzheimer dementia. Neurology. 2007, 68: 288-291. 10.1212/01.wnl.0000252358.03285.9d.

31.

Palmer K, Wang HX, Bäckman L, Winblad B, Fratiglioni L: Differential evolution of cognitive impairment in nondemented older persons: results from the Kungsholmen project. Am J Psychiatry. 2002, 159: 436-442. 10.1176/appi.ajp.159.3.436.

32.

Loewenstein DA, Acevedo A, Agron J, Duara R: Stability of neurocognitive impairment in different subtypes of mild cognitive impairment. Dement Geriatr Cogn Disord. 2007, 23: 82-86. 10.1159/000097304.

33.

Diniz BS, Nunes PV, Yassuda MS, Forlenza O: Diagnosis of mild cognitive impairment revisited after one year. Preliminary results of a prospective study. Dement Geriatr Cogn Disord. 2009, 27: 224-231. 10.1159/000203346.

34.

Tyas SL, Salazar JC, Snowdon DA, Desrosiers MF, Riley KP, Mendiondo MS, Kryscio RJ: Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study. Am J Epidemiol. 2007, 165: 1231-1238. 10.1093/aje/kwm085.PubMedCentral

35.

Burton CL, Strauss E, Bunce D, Hunter MA, Hultsch DF: Functional abilities in older adults with mild cognitive impairment. Gerontology. 2009, 55: 570-581. 10.1159/000228918.

36.

Kim KR, Lee KS, Cheong HK, Eom JS, Oh BH, Hong CH: Characteristic profiles of instrumental activities of daily living in different subtypes of mild cognitive impairment. Dement Geriatr Cogn Disord. 2009, 27: 278-285. 10.1159/000204765.

37.

Wadley VG, Okonkwo O, Crowe M, Ross-Meadows LA: Mild cognitive impairment and everyday function: evidence of reduced speed in performing instrumental activities of daily living. Am J Geriatr Psychiatry. 2008, 16: 416-424.

38.

Jefferson AL, Byerly LK, Vanderhill S, Lambe S, Wong S, Ozonoff A, Karlawish JH: Characterization of activities of daily living in individuals with mild cognitive impairment. Am J Geriatr Psychiatry. 2008, 16: 375-383. 10.1097/JGP.0b013e318162f197.PubMedCentral

39.

Rozzini L, Chilovi BV, Conti M, Bertoletti E, Delrio I, Trabucchi M, Padovani A: Conversion of amnestic mild cognitive impairment to dementia of Alzheimer type is independent to memory deterioration. Int J Geriatr Psychiatry. 2007, 22: 1217-1222. 10.1002/gps.1816.

40.

Jorm AF: Assessment of cognitive impairment and dementia using informant report. Clin Psychol Rev. 1996, 16: 51-73. 10.1016/0272-7358(95)00056-9.

41.

Abreu ID, Nunes PV, Diniz BS, Forlenza OV: Combining functional scales and cognitive tests in screening for mild cognitive impairment at a university-based memory clinic in Brazil. Rev Bras Psiquiatr. 2008, 30: 346-349.

42.

Pereira FS, Yassuda MS, Oliveira AM, Diniz BS, Radanovic M, Talib LL, Gattaz WF, Forlenza OV: Profiles of functional deficits in mild cognitive impairment and dementia: benefits from objective measurement. J Int Neuropsychol Soc. 2010, 16: 297-305. 10.1017/S1355617709991330.

43.

Pereira FS, Oliveira AM, Diniz BS, Forlenza OV, Yassuda MS: Cross-cultural adaptation, reliability and validity of the DAFS-R in a sample of Brazilian older adults. Arch Clin Neuropsychol. 2010, 25: 335-343. 10.1093/arclin/acq029.

44.

Wagner JA: Biomarkers: principles, policies, and practice. Clin Pharmacol Ther. 2009, 86: 3-7. 10.1038/clpt.2009.77.

45.

Reiber H: Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta. 2001, 310: 173-186. 10.1016/S0009-8981(01)00573-3.

46.

Wiltfang J, Lewczuk P, Riederer P, Grünblatt E, Hock C, Scheltens P, Hampel H, Vanderstichele H, Iqbal K, Galasko D, Lannfelt L, Otto M, Esselmann H, Henkel AW, Kornhuber J, Blennow K: Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J Biol Psychiatry. 2005, 6: 69-84. 10.1080/15622970510029786.

47.

Buerger K, Ewers M, Pirttilä T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H: CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006, 129: 3035-3041. 10.1093/brain/awl269.

48.

Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW, Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM, Trojanowski JQ: Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch Neurol. 2003, 60: 1696-1702. 10.1001/archneur.60.12.1696.

49.

Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T: Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009, 66: 382-389. 10.1001/archneurol.2008.596.

50.

Blennow K, Hampel H: CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003, 2: 605-613. 10.1016/S1474-4422(03)00530-1.

51.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006, 5: 228-34. 10.1016/S1474-4422(06)70355-6.

52.

Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K: Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001, 58: 373-379. 10.1001/archneur.58.3.373.

53.

Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A: Cerebrospinal fluid tau and β-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol. 2002, 59: 1729-1734. 10.1001/archneur.59.11.1729.

54.

Arai H, Ishiguro K, Ohno H, Moriyama M, Itoh N, Okamura N, Matsui T, Morikawa Y, Horikawa E, Kohno H, Sasaki H, Imahori K: CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol. 2000, 166: 201-203. 10.1006/exnr.2000.7501.

55.

Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K: Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry. 2004, 9: 705-710.

56.

Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative: Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009, 65: 403-413. 10.1002/ana.21610.PubMedCentral

57.

Forlenza OV, Diniz BS, Talib LL, Radanovic M, Yassuda MS, Ojopi EB, Gattaz WF: Clinical and biological predictors of Alzheimer's disease in patients with amnestic mild cognitive impairment. Rev Bras Psiquiatr. 2010, 32: 216-222. 10.1590/S1516-44462010005000002.

58.

Diniz B, Pinto J, Forlenza OV: Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry. 2008, 9: 172-182. 10.1080/15622970701535502.

59.

Mattsson N, Blennow K, Zetterberg H: Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Clin Chem lab Med. 2010, 48: 603-607. 10.1515/CCLM.2010.131.

60.

Blennow K, Hampel H, Weiner M, Zetterberg H: Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010, 6: 131-144. 10.1038/nrneurol.2010.4.

61.

Santos AN, Torkler S, Nowak D, Schlittig C, Goerdes M, Lauber T, Trischmann L, Schaupp M, Penz M, Tiller FW, Böhm G: Detection of amyloid-β oligomers in human cerebrospinal fluid by flow cytometry and fluorescence resonance energy transfer. J Alzheimers Dis. 2007, 11: 117-125.

62.

Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, Allsop D, Nakagawa M: High-molecular-weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J. 2010, 24: 2716-2726. 10.1096/fj.09-150359.

63.

Englund H, Degerman Gunnarsson M, Brundin RM, Hedlund M, Kilander L, Lannfelt L, Pettersson FE: Oligomerization partially explains the lowering of Aβ42 in Alzheimer's disease cerebrospinal fluid. Neurodegener Dis. 2009, 6: 139-147. 10.1159/000225376.

64.

Busatto GF, Diniz BS, Zanetti MV: Voxel-based morphometry in Alzheimer's disease. Expert Rev Neurother. 2008, 8: 1691-1702. 10.1586/14737175.8.11.1691.

65.

Apostolova LG, Dinov ID, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Thompson PM: 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease. Brain. 2006, 129: 2867-2873. 10.1093/brain/awl274.

66.

Seo SW, Im K, Lee JM, Kim YH, Kim ST, Kim SY, Yang DW, Kim SI, Cho YS, Na DL: Cortical thickness in single-versus multiple-domain amnestic mild cognitive impairment. NeuroImage. 2007, 36: 289-297. 10.1016/j.neuroimage.2007.02.042.

67.

Singh V, Chertkow H, Lerch JP, Evans AC, Dorr AE, Kabani NJ: Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer's disease. Brain. 2006, 129: 2885-2893. 10.1093/brain/awl256.

68.

Davatzikos C, Xu F, An Y, Fan Y, Resnick SM: Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index. Brain. 2009, 132: 2026-2035. 10.1093/brain/awp091.PubMedCentral

69.

Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC, Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology. 2003, 60: 1374-1377.

70.

Chetelat G, Eustache F, Viader F, De La Sayette V, Pölerin A, Mäzenge F, Hannequin D, Dupuy B, Baron JC, Desgranges B: FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase. 2005, 11: 14-25. 10.1080/13554790490896938.

71.

Tapiola T, Pennanen C, Tapiola M, Tervo S, Kivipelto M, Hänninen T, Pihlajamäki M, Laakso MP, Hallikainen M, Hämäläinen A, Vanhanen M, Helkala EL, Vanninen R, Nissinen A, Rossi R, Frisoni GB, Soininen H: MRI of hippocampus and entorhinal cortex in mild cognitive impairment: a follow-up study. Neurobiol Aging. 2008, 29: 31-38. 10.1016/j.neurobiolaging.2006.09.007.

72.

Hämäläinen A, Tervo S, Grau-Olivares M, Niskanen E, Pennanen C, Huuskonen J, Kivipelto M, Hänninen T, Tapiola M, Vanhanen M, Hallikainen M, Helkala EL, Nissinen A, Vanninen R, Soininen H: Voxel-based morphometry to detect brain atrophy in progressive mild cognitive impairment. NeuroImage. 2007, 37: 1122-1131.

73.

Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, Fox NC: Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol. 2006, 5: 828-834. 10.1016/S1474-4422(06)70550-6.

74.

Ferreira LK, Diniz BS, Forlenza OV, Busatto GF, Zanetti MV: Neurostructural predictors of Alzheimer's disease: a meta-analysis of VBM studies. Neurobiol Aging.

75.

Mielke R, Pietrzyk U, Jacobs A, Fink GR, Ichimiya A, Kessler J, Herholz K, Heiss WD: HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern. Eur J Nucl Med. 1994, 21: 1052-1060. 10.1007/BF00181059.

76.

Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frölich L, Schönknecht P, Ito K, Mielke R, Kalbe E, Zändorf G, Delbeuck X, Pelati O, Anchisi D, Fazio F, Kerrouche N, Desgranges B, Eustache F, Beuthien-Baumann B, Menzel C, Schröder J, Kato T, Arahata Y, Henze M, Heiss WD: Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002, 17: 302-316. 10.1006/nimg.2002.1208.

77.

Nobili F, Salmaso D, Morbelli S, Girtler N, Piccardo A, Brugnolo A, Dessi B, Larsson SA, Rodriguez G, Pagani M: Principal component analysis of FDG PET in amnestic MCI. Eur J Nucl Med Mol Imaging. 2008, 35: 2191-2202. 10.1007/s00259-008-0869-z.

78.

Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, Reiman EM, Holthoff V, Kalbe E, Sorbi S, Diehl-Schmid J, Perneczky R, Clerici F, Caselli R, Beuthien-Baumann B, Kurz A, Minoshima S, de Leon MJ: Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 2008, 49: 390-398. 10.2967/jnumed.107.045385.PubMedCentral

79.

Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC: Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology. 2003, 60: 1374-1377.

80.

Chetelat G, Landeau B, Eustache F, Mezenge F, Viader F, de la Sayette V, Desgranges B, Baron JC: Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. NeuroImage. 2005, 27: 934-946. 10.1016/j.neuroimage.2005.05.015.

81.

Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, Salmon E, Baron JC, De Cristofaro MT, Padovani A, Borroni B, Franceschi M, Bracco L, Pupi A: MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology. 2004, 63: 2332-2340.

82.

DeLeon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, Tsui W, Kandil E, Scherer AJ, Roche A, Imossi A, Thorn E, Bobinski M, Caraos C, Lesbre P, Schlyer D, Poirier J, Reisberg B, Fowler J: Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-d-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci USA. 2001, 98: 10966-10971. 10.1073/pnas.191044198.

83.

Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, Minoshima S, Schwaiger M, Kurz A: Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med. 2005, 46: 1625-1632.

84.

Mathis C, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk W: Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003, 46: 2740-2754. 10.1021/jm030026b.

85.

Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004, 55: 306-319. 10.1002/ana.20009.

86.

Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL, Kung HP, Zhang W, Kung MP, Skovronsky D, Dyrks T, Holl G, Krause S, Friebe M, Lehman L, Lindemann S, Dinkelborg LM, Masters CL, Villemagne VL: Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008, 7: 129-135. 10.1016/S1474-4422(08)70001-2.

87.

Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR: PET of brain amyloid and tau in mild cognitive impairment. New Engl J Med. 2006, 355: 2652-2663. 10.1056/NEJMoa054625.

88.

Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, Hotton G, Cutler D, Fox N, Kennedy A, Rossor M, Brooks DJ: Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007, 68: 501-508. 10.1212/01.wnl.0000244749.20056.d4.

89.

Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM: Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann Neurol. 2006, 59: 512-519. 10.1002/ana.20730.

90.

Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM: Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med. 2009, 1: 371-380. 10.1002/emmm.200900048.PubMedCentral

91.

Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, Oikonen V, Kailajärvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO: PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology. 2007, 68: 1603-1606. 10.1212/01.wnl.0000260969.94695.56.

92.

Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Langström B, Nordberg A: PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008, 29: 1456-1465. 10.1016/j.neurobiolaging.2007.03.029.

93.

Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Nagren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ: Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology. 2009, 73: 754-760. 10.1212/WNL.0b013e3181b23564.PubMedCentral

94.

Villemagne V, Pike KE, Darby D, Maruff P, Savage G, Ng S, Ackermann U, Cowie TF, Currie J, Chan SG, Jones G, Tochon-Danguy H, O'Keefe G, Masters CL, Rowe CC: Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia. 2008, 46: 1688-1697. 10.1016/j.neuropsychologia.2008.02.008.

95.

Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE: Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008, 65: 1509-1517. 10.1001/archneur.65.11.1509.PubMedCentral

96.

Resnick SM, Sojkova J, Zhou Y, An Y, Ye W, Holt DP, Dannals RF, Mathis CA, Klunk WE, Ferrucci L, Kraut MA, Wong DF: Longitudinal cognitive decline is associated with fibrillar amyloid-β measured by [11C]PiB. Neurology. 2010, 74: 807-815. 10.1212/WNL.0b013e3181d3e3e9.PubMedCentral

97.

Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ: Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA. 2009, 106: 6820-6825. 10.1073/pnas.0900345106.PubMedCentral

98.

Fagan A, Roe CM, Xiong C, Mintun MA, Morris J, Holtzman D: Cerebrospinal fluid tau/β-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007, 64: 343-349. 10.1001/archneur.64.3.noc60123.

99.

Fellgiebel A, Siessmeier T, Scheurich A, Winterer G, Bartenstein P, Schmidt LG, Möller MJ: Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment. Biol Psychiatry. 2004, 56: 279-283. 10.1016/j.biopsych.2004.05.014.

100.

Bouwman FH, Schoonenboom SN, van der Flier WM, van Elk EJ, Kok A, Barkhof F, Blankenstein MA, Scheltens P: CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging. 2007, 28: 1070-1074. 10.1016/j.neurobiolaging.2006.05.006.

101.

Josephs KA, Whitwell JL, Ahmed Z, Shiung MM, Weigand SD, Knopman DS, Boeve BF, Parisi JE, Petersen RC, Dickson DW, Jack CR: Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol. 2008, 63: 204-212. 10.1002/ana.21223.PubMedCentral

102.

Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S: Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging. 2009, 30: 165-173. 10.1016/j.neurobiolaging.2007.06.009.

103.

J Jack CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC, the Alzheimer's Disease Neuroimaging Initiative: Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009, 132: 1355-1365. 10.1093/brain/awp062.

104.

Walhovd KB, Fjell AM, Brewer J, McEvoy LK, Fennema-Notestine C, Hagler DJ, Jennings RG, Karow D, Dale AM, the Alzheimer's Disease Neuroimaging Initiative: Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. Am J Neuroradiol. 2010, 31: 347-354. 10.3174/ajnr.A1809.PubMedCentral

105.

Stomrud E, Hansson O, Blennow K, Minthon L, Londos E: Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord. 2007, 24: 118-124. 10.1159/000105017.

106.

Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E: Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol. 2010, 67: 217-223. 10.1001/archneurol.2009.316.

107.

Sperling R, Beckett L, Bennett D, Craft S, Fagan A, Kaye J, Montine T, Park D, Reiman E, Siemers E, Stern Y, Yaffe K, Preclinical Alzheimer's Disease Workgroup: Criteria for preclinical Alzheimer's disease. [http://www.alz.org/research/diagnostic_criteria/preclinical_recommendations.pdf]

108.

Riley KP, Snowdon DA, Markesbery WR: Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study. Ann Neurol. 2002, 51: 567-577. 10.1002/ana.10161.

109.

Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P: Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6: 734-746. 10.1016/S1474-4422(07)70178-3.

110.

Petersen RC, Knopman DS: MCI is a clinically useful concept. Int Psychogeriatr. 2006, 18: 394-314.

111.

Citron M: Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov. 2010, 9: 387-398. 10.1038/nrd2896.

112.

Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD, Rogers J, Siemers E, Trojanowski JQ, National Institute on Aging Biological Markers Working G: Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging. 2003, 24: 521-536. 10.1016/S0197-4580(03)00002-2.

113.

Mortimer JA, Petersen RC: Detection of prodromal Alzheimer's disease. Ann Neurol. 2008, 64: 479-480. 10.1002/ana.21552.

114.

Sloane PD, Zimmerman S, Suchindran C, Reed P, Wang L, Boustani M, Sudha S: The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health. 2002, 23: 213-231. 10.1146/annurev.publhealth.23.100901.140525.

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1741-7015/8/89/prepub

Title: Diagnosis and biomarkers of predementia in Alzheimer's disease
Authors: Orestes V Forlenza
Breno S Diniz
Wagner F Gattaz
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: BMC Medicine / Issue 1/2010
Electronic ISSN: 1741-7015
DOI: https://doi.org/10.1186/1741-7015-8-89

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Diagnosis and biomarkers of predementia in Alzheimer's disease

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Reduced acquisition and reactivation of human papillomavirus infections among older women treated with cryotherapy: results from a randomized trial in South Africa

Recent advances in radiotherapy

The effects of increased dose of exercise-based therapies to enhance motor recovery after stroke: a systematic review and meta-analysis

Caesarean section without medical indications is associated with an increased risk of adverse short-term maternal outcomes: the 2004-2008 WHO Global Survey on Maternal and Perinatal Health

Normalisation process theory: a framework for developing, evaluating and implementing complex interventions

Enhancement drugs: are there limits to what we should enhance and why?